Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anatara Lifesciences has provided an update on the evaluation of Detach, which aids in the control of scour in piglets
  • It has been determined that the best way to launch Detach in Australia is via an agreement with an animal health partner
  • Anatara has also further evaluated the regulatory requirements for species other than piglets

Anatara Lifesciences has provided an update on the evaluation of Detach, its non-antibiotic, animal health asset, which aids in the control of scour in piglets.

Scour (diarrhoea) in piglets is an expensive, delimitating and in some cases a life-threatening condition.

Ever since Anatara was listed in 2014 it is aiming to increase survivability and provide health benefits to pre-weaning piglets.

As the company moves forward the Board believes that a substantial market opportunity for Detach exists which will hopefully minimise scour on farms.

Currently, effective and registered alternatives to antibiotics in treating scour are limited. However, zinc oxide was historically used by pig farmers as an alternative to antibiotics but from 2022 high dosage zinc oxide will no longer be able to be used in the European Union.

Detach is a non-antibiotic approach to treat scour and uses bromelain, an extract from pineapple stems.

In October 2018 Anatara announced that The Australian Pesticides and Veterinary Medicines Authority had registered Detach for use in piglets in Australia.

This registering allows the potential fast track product registration within 12 months to South East Asia, in areas such as Vietnam, Myanmar and the Philippines.

However, as other individual countries have varying requirements for regulatory approval many of them require additional field trials.

Following extensive reviews. Anatara has determined the best way to launch Detach into the Australian market is through an agreement with an animal health partner.

Anatara has also further evaluated the regulatory requirements for species other than piglets and has concluded that considerable development work is required for Detach to be approved for use in other species.

“We continue to believe in the value of Anatara’s animal health assets, however, it is clear that further investment is required to realise this,” Anatara CEO Steve Lydeamore.

“It is our intent to achieve success through partnering with multi-national animal health companies.”

Updates will be provided as activities progress.

ANR by the numbers
More From The Market Herald
The Market Herald Video

" Next Science’s (ASX:NXS) CEO submits resignation

Next Science’s (ASX:NXS) CEO has announced her intention to retire before June 30, 2023.
The Market Herald Video

" Race Oncology (ASX:RAC) completes first-phase Zantrene leukaemia trial

Cancer treatment company Race Oncology (ASX:RAC) has completed the latest stage of its first-phase trial for…
The Market Herald Video

" Immutep (ASX:IMM) publishes “favourable” interim data from second-phase efti trial

Immutep (ASX:IMM) has published new interim data from Part A of its second-phase TACTI-002 trial showing…

" Microba Life Sciences (ASX:MAP) partners with Midnight Health

Microba Life Sciences (ASX:MAP) has signed a strategic partnership agreement with healthcare company, Midnight Health, to…